|Table of Contents|

Evaluation value of MRP score combined with IPSI score in prognosis of newly diagnosed multiple myeloma patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 09
Page:
1726-1731
Research Field:
Publishing date:

Info

Title:
Evaluation value of MRP score combined with IPSI score in prognosis of newly diagnosed multiple myeloma patients
Author(s):
YE Jiannan; MA Kewa; CAO Yongqin; ZHOU Xin; SUN Chao
Department of Haematology,Wuxi People's Hospital Affiliated to Nanjing Medical University，Jiangsu Wuxi 214023,China.
Keywords:
multiple myeloma; prognostic evaluation; bortezomib
PACS:
R733.3
DOI:
10.3969/j.issn.1672-4992.2023.09.027
Abstract:
Objective:To explore the prognostic value of UK myeloma research alliance risk profile prognostic scoring system and inflammatory prognostic scoring index prognostic scoring system in the real world for newly diagnosed multiple myeloma patients based on bortezomib treatment.Methods:The clinical and laboratory data of patients with initial multiple myeloma in the Department of Hematology of our hospital from January 1，2007 to June 30，2018 were retrospectively analyzed.Two prognostic scoring systems were used to evaluate and compare the prognosis of patients.Results:Both MRP prognostic scoring system and IPSI prognostic scoring system can stratify the risk of newly diagnosed patients with multiple myeloma.The OS and PFS of patients in the low risk or high risk group who met both MRP and IPSI definitions were significantly different from those in other groups.Conclusion:Myeloma patients with both high risk factors for MRP and high risk factors for IPSI belong to ultra-high risk patients with extremely poor prognosis.The comprehensive application of the two simple prognostic models can be used as a supplement to the existing mainstream prognostic models.

References:

［1］SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics, 2022［J］.CA:A Cancer Journal for Clinicians,2022,72(1):7-33.
［2］COWAN AJ，GREEN DJ，KWOK M，et al.Diagnosis and management of multiple myeloma：A review［J］.JAMA，2022，327(5):464-477.
［3］COOK G，ROYLE KL，PAWLYN C，et al.A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma(UK myeloma research alliance risk profile)：a development and validation study［J］.Lancet Haematol，2019，6(3):e154-166.
［4］LIU SW，SHI J，GUO H，et al.Prognostic significance of the inflammatory index-based scoring system in patients preliminarily diagnosed with multiple myeloma in the bortezomib-based chemotherapy era［J］.Cancer Manag Res，2019，11:9409-9420.
［5］ATTAL M，LAUWERS-CANCES V，HULIN C，et al.Lenalidomide，bortezomib，and dexamethasone with transplantation for myeloma［J］.N Engl J Med，2017，376(14):1311-1320.
［6］CORRE J，PERROT A，CAILLOT D，et al.Del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma［J］.Blood，2021，137(9):1192-1195.
［7］WANG YT，BAO L，CHU B，et al.Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis［J］.J Clin Lab Anal，2022，36(7):e24375.
［8］WANG W，XU SW，ZHU XY，et al.Identification and validation of a novel RNA-binding protein-related gene-based prognostic model for multiple myeloma［J］.Front Genet，2021，12:665173.
［9］ZHOU S，FANG J，SUN Y，et al.Integrated analysis of a risk score system predicting prognosis and a ceRNA network for differentially expressed lncRNAs in multiple myeloma［J］.Front Genet，2020，11:934.
［10］WALKER BA，MAVROMMATIS K，WARDELL CP，et al.A high-risk，double-hit，group of newly diagnosed myeloma identified by genomic analysis［J］.Leukemia，2019，33(1):159-170.
［11］REDDER L，KLAUSEN TW，VANGSTER AJ，et al.Validation of the UK myeloma research alliance risk profile，a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation；a population-based study from the Danish national multiple myeloma registry［J］.Br J Haematol，2021，193(1):119-124.
［12］DJEBBARI F，RAMPOTAS A，PANITSAS F，et al.Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model(myeloma risk profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients［J］.PLoS One,2022，17(1):e0262388.
［13］王昕，张丽娜，金媛媛，等.英国骨髓瘤联盟风险评分在初诊多发性老年骨髓瘤患者疗效及预后中的应用［J］.中华老年医学杂志，2022,41(6):684-687. WANG X,ZHANG LN,JIN YY,et al.An application of UK myeloma research alliance risk profile for the evaluation of efficacy and prognosis in elderly patients with newly diagnosed multiple myeloma［J］.Chinese Journal of Geriatrics,2022,41(6):684-687.
［14］MA K，YE J，WANG L，et al.Evaluation of the UK myeloma research alliance risk profile in Chinese patients with newly diagnosed multiple myeloma without autologous stem cell transplantation［J］.Onco Targets Ther，2021，14:2349-2361.
［15］FACON T，KUMAR S，PLESNER T，et al.Daratumumab plus lenalidomide and dexamethasone for untreated myeloma［J］.N Engl J Med，2019，380(22):2104-2115.
［16］GERALDES C，NEVES M，CHACIM S，et al.Practical considerations for the daratumumab management in portuguese routine clinical practice：Recommendations from an expert panel of hematologists［J］.Front Oncol，2022，11:817762.

Memo

Memo:
-
Last Update: 2023-03-30